Azole-based antifungal prophylaxis in high-risk patients by region and type of agent (fluconazole versus mould-active extended-spectrum azoles).
| . | USA,* 2001 . | Japan,** 2001 . | Europe,† 2005 . | |||
|---|---|---|---|---|---|---|
| . | FLU . | ESA . | FLU . | ESA . | FLU . | ESA . |
| * Trifilio S et al. (A survey of 31 transplant centers in the United States encompassing over 3400 transplants performed in 2001. Almost all (93%) reported using some form of antifungal prophylaxis). Bone Marrow Transplant . 2004 ;33 :735 –9 | ||||||
| ** Imataki O et al. (A survey among 63 transplant centers encompassing 48% of all HSCT performed in Japan in 2001. All (100%) patients undergoing autologous, myeloablative and nonmyeloablative HSCT received antifungal chemoprophylaxis). Bone Marrow Transplant . 2004 ;33 :1173 –9 | ||||||
| † Round Table, European Conference on Infections in Leukemia, 14th Symposium on Infections in the Immunocompromised Host, Crans-Montana, Switzerland, July 2–5, 2006. | ||||||
| Abbreviations: Auto HSCT, autologous hematopoietic stem cell transplant; Allo HSCT, allogeneic hematopoietic stem cell transplant; FLU, fluconazole; ESA, extended-spectrum mould-active azoles (itraconazole, voriconazole, posaconazole). | ||||||
| Auto HSCT | 84% | 3% | 72% | 18% | 53% | 36% |
| Allo HSCT | 67% | 13% | 79% | 4% | 57% | 33% |
| Acute leukemia | — | — | — | — | 55% | 35% |
| . | USA,* 2001 . | Japan,** 2001 . | Europe,† 2005 . | |||
|---|---|---|---|---|---|---|
| . | FLU . | ESA . | FLU . | ESA . | FLU . | ESA . |
| * Trifilio S et al. (A survey of 31 transplant centers in the United States encompassing over 3400 transplants performed in 2001. Almost all (93%) reported using some form of antifungal prophylaxis). Bone Marrow Transplant . 2004 ;33 :735 –9 | ||||||
| ** Imataki O et al. (A survey among 63 transplant centers encompassing 48% of all HSCT performed in Japan in 2001. All (100%) patients undergoing autologous, myeloablative and nonmyeloablative HSCT received antifungal chemoprophylaxis). Bone Marrow Transplant . 2004 ;33 :1173 –9 | ||||||
| † Round Table, European Conference on Infections in Leukemia, 14th Symposium on Infections in the Immunocompromised Host, Crans-Montana, Switzerland, July 2–5, 2006. | ||||||
| Abbreviations: Auto HSCT, autologous hematopoietic stem cell transplant; Allo HSCT, allogeneic hematopoietic stem cell transplant; FLU, fluconazole; ESA, extended-spectrum mould-active azoles (itraconazole, voriconazole, posaconazole). | ||||||
| Auto HSCT | 84% | 3% | 72% | 18% | 53% | 36% |
| Allo HSCT | 67% | 13% | 79% | 4% | 57% | 33% |
| Acute leukemia | — | — | — | — | 55% | 35% |